DAAs show good cure rates and liver function improvement for transplant recipients with recurrent HCV
AbbVie 3D regimen cures recurrent HCV in most liver transplant recipients without cirrhosis
NHS urgently needs to make PrEP available, say HIV prevention organisations
Tenofovir continues to suppress hepatitis B virus for eight years
Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C
Positive response to 'gift tokens for undetectable viral load' trial
AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection
Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients
